drug

naratriptan

MeSH C106783
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by UMC Utrecht
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order
NCT00282165Phase 4Terminated

KOLs & investigators

5
Henk Nijman, PhD
Berend Olivier, PhD
Frank Koerselman, MD, PhD
Adriano van der Loo, MD
Rob L. van Ojen, MD, PhD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
UMC Utrecht
company
trial
Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order
PHASE4
trial
indication
Intermittent Explosive Disorder
indication
Impulse Regulation Disorder
indication
Disruptive, Impulse Control, and Conduct Disorders
indication
Psychotic Disorders
indication
KOL
Henk Nijman, PhD
KOL score —
person
Berend Olivier, PhD
KOL score —
person
Frank Koerselman, MD, PhD
KOL score —
person
Adriano van der Loo, MD
KOL score —
person